Bioxyne Secures $50 Million German Supply Contract with ADREXpharma

Significant Expansion in German Medicinal Cannabis Market

Bioxyne Limited (ASX:BXN) has taken a decisive step to cement its presence in Europe’s largest medicinal cannabis market by securing a two-year, $50 million supply agreement with German pharmaceutical company ADREXpharma GmbH. This deal not only guarantees a $25 million minimum purchase in the first 12 months but also grants ADREX exclusive rights to distribute Bioxyne’s Dr Watson® brand across Germany, providing near-term revenue visibility and a clear sales pathway into the continent.

The contract represents a substantial expansion over the initial supply agreement signed in June 2025, reflecting growing demand for Bioxyne’s GMP-certified cannabis products. Supply volumes will comprise Australian GMP-manufactured cannabis flower and other medicinal products, distributed through ADREX’s established network of pharmacies and healthcare providers.

Bioxyne’s Chief Executive Officer Sam Watson highlighted the deal’s importance, noting it "reflects the scale and momentum we are building in new markets" and bolsters the company’s position across key regulated European markets. While medicinal cannabis remains the core of Bioxyne’s business, the company is actively pursuing opportunities to diversify its pharmaceutical portfolio into additional controlled substances with emerging therapeutic applications.

Strategic Partnership with ADREXpharma Strengthens Market Access

ADREXpharma, a licensed importer, manufacturer, and wholesale distributor operating under Germany’s stringent pharmaceutical regulations, has built a robust operational framework with Bioxyne over the past six months. CEO Nicole Broockmann emphasised that the partnership has refined product quality and supply chain logistics, positioning both companies to meet the demands of Germany’s rapidly expanding medicinal cannabis market, now estimated at over 200 tonnes per annum.

The exclusive rights to the Dr Watson® brand in Germany underpin targeted market penetration efforts, leveraging ADREX’s local distribution expertise and pharmacy network. This aligns with Bioxyne’s broader strategy to scale its GMP-certified manufacturing and supply platform internationally, focusing on regulated markets like Germany and the United Kingdom where patient demand and regulatory frameworks continue to evolve.

Broader Growth Trajectory and International Expansion

This agreement complements Bioxyne’s recent international expansion milestones, including its first medicinal cannabis flower supply to Costa Rica, which established an early foothold in Latin America. The German deal adds to a growing portfolio of supply contracts and manufacturing partnerships, such as those with Aurora Cannabis, which have helped Bioxyne post record revenues and expand its pharmaceutical-grade cannabis offerings globally.

Bioxyne’s subsidiary Breathe Life Sciences (BLS) operates as a GMP-licensed manufacturer and distributor of controlled substances including medicinal cannabis, psilocybin, and MDMA. With manufacturing and distribution centres across Australia, Japan, the UK, and Europe, BLS is well-positioned to capitalise on the increasing acceptance and demand for alternative therapeutics and investigational medicines.

The expanded German supply contract with ADREXpharma thus marks a critical step in Bioxyne’s ambition to become a significant supplier in regulated international markets, leveraging its proprietary brands and manufacturing capabilities to capture growing opportunities beyond its established Australian base.